Drug Profile
KES 0001
Alternative Names: DTP3; KES-0001Latest Information Update: 31 May 2022
Price :
$50
*
At a glance
- Originator Imperial College of Science, Technology and Medicine
- Class Antineoplastics
- Mechanism of Action GADD45B protein inhibitors; Gene expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Diffuse large B cell lymphoma; Multiple myeloma
Most Recent Events
- 30 Sep 2021 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Late-stage disease, Second-line therapy or greater) in United Kingdom (unspecified route) (ISRCTN13777452)
- 30 Sep 2021 Phase-I/II clinical trials in Multiple myeloma (Late-stage disease, Second-line therapy or greater) in United Kingdom (unspecified route) (ISRCTN13777452)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Multiple-myeloma in United Kingdom